APCEDEN® Personalized Cancer Therapy
Empowering your body's defense system to fight cancer through personalized immunotherapy.
APCEDEN® Immunotherapy
APAC Biotech's Dendritic cell (DC) Immunotherapy, APCEDEN®, aims at enabling the patient’s immune system to recognise these tumor cells and destroy them. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer, to offer longer-term protection against the disease with comparatively minimum side effects.
How APCEDEN® Works
Cancer Patient’s own monocytes (WBCs) are used along with patient’s own tumor tissue to create a population of Dendritic Cells specific to the patient’s "Cancer" such that when administered, it boosts the patient’s immune response (activates the T-lymphocytes) thereby recognising, attacking and destroying the tumor cells.
Patient’s have shown reduction in the size of their lesions, a significant survival benefit as well as improvement in their Quality of Life (QOL). Moreover, this technology can also be given adjuvantly with other treatment modalities without contra-indications.
Since the dendritic cell based cancer treatment is completely self derived (autologous in nature), there are minimal side effects.
APAC Biotech Timeline
- Personalized Treatment
APCEDEN® is tailored to each patient’s unique cancer profile, ensuring the immune system targets cancer cells with precision.
- Minimal Side Effects
As APCEDEN® uses the patient's own cells, there is a lower risk of side effects compared to conventional cancer treatments like chemotherapy and radiation.
- Long-Term Protection
By training the immune system to recognize cancer cells, APCEDEN® offers not only immediate treatment but also long-term protection against recurrence.
- Combinable with Other Treatments
APCEDEN® can be used alongside other therapies without complications, making it a versatile option in cancer treatment plans.
Why Dendritic Cells Matter
Dendritic Cells are effective professional "Antigen Presenting Cells (APCs)" that express MHC I and MHC II molecules. In other words, their function is to recognise tumor proteins/infectious agents, engulf them and to express specific antigenic peptides derived from them on their surface.
How Dendritic Cells Fight Cancer
When mature Dendritic Cells interact with resting T-Lymphocytes (Immune cells responsible for attacking tumor cells), upon proper signalling, they activate these resting T-lymphocytes to become "activated T-lymphocytes" (CTLs, Cytotoxic-T lymphocytes). The CTLs now circulate in blood and divide to proliferate and increase their number exponentially. The CTLs can recognise the specific tumor cells (as educated by mature Dendritic Cells) and destroy them. APAC’s Dendritic Cell product APCEDEN®, utilises this process to make a "Dendritic Cell based Therapeutic Cancer Vaccine " for each cancer patient personalised according to their specific Cancer Tumor.
